Clinical Trials & Research Studies

A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects with Moderate to severe Hidradenitis Suppurativa


Brief description of study

Primary objective The primary objective of this study is to evaluate the efficacy of bimekizumab in subjects with moderate to severe HS.

Secondary objective The secondary objective of this study is to assess the safety, tolerability, immunogenicity, and PK of bimekizumab in subjects with moderate to severe HS.

Clinical Study Identifier: NCT03248531

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects with Moderate to severe Hidradenitis Suppurativa
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.